2. Signaling Pathways
  3. Anti-infection
  4. RSV

RSV

Respiratory syncytial virus

RSV

Related Products

PDF 0.17 MB

RSV (Respiratory syncytial virus) is a leading cause of acute respiratory infections. RSV can exploit host immunity and cause a strong inflammatory response that leads to lung damage and virus dissemination. There is a single RSV serotype with two major antigenic subgroups, A and B.

RSV is a non-segmented negative-sense single-stranded enveloped RNA virus that belongs to the family of Paramyxoviridae, genus Pneumovirus, subfamily Pneumovirinae. Its 10 genes encode 11 proteins since two overlapping open reading frames in the M2 mRNA yield two distinct matrix proteins, M2-1 and M2-2. The viral envelope contains three proteins, the G glycoprotein, the fusion (F) glycoprotein, and the small hydrophobic (SH) protein. The RSV virus comprises five other structural proteins, the large (L) protein, nucleocapsid (N), phosphoprotein (P), matrix (M), and M2-1, and two non-structural proteins (NS1 and NS2).

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0434
    Ribavirin
    		Inhibitor 99.80%
    Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIVl, and RSV. Ribavirin also has anti-orthopoxvirus and anti-variola activities.
    Ribavirin
  • HY-15455
    Roflumilast
    		Inhibitor 99.98%
    Roflumilast (APTA-2217) is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells.
    Roflumilast
  • HY-104032
    Ac-CoA Synthase Inhibitor1
    		Inhibitor 99.33%
    Ac-CoA Synthase Inhibitor1 is a potent, reversible acetate-dependent acetyl-CoA synthetase 2 (ACSS2) inhibitor with an IC50 of 0.6 µM. Ac-CoA Synthase Inhibitor1 inhibits the respiratory syncytial virus (RSV).
    Ac-CoA Synthase Inhibitor1
  • HY-N0662
    Amentoflavone
    		Inhibitor 99.81%
    Amentoflavone (Didemethyl-ginkgetin) is a potent and orally active GABA(A) negative modulator. Amentoflavone also shows anti-inflammatory, antioxidative, anti-viral, anti-tumor, anti-radiation, anti-fungal, antibacterial activity. Amentoflavone induces apoptosis and cell cycle arrest at sub-G1 phase.
    Amentoflavone
  • HY-126303C
    GS-443902 trisodium
    		Inhibitor 99.98%
    GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC50s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734).
    GS-443902 trisodium
  • HY-N12305
    4,5-O-Dicaffeoyl quinic acid methyl ester
    		Inhibitor
    4,5-O-Dicaffeoyl quinic acid methyl ester (compound 4), a dicaffeoylquinic acid, has potent antiviral activity against respiratory syncytial virus (RSV) with an IC50 of 0.63 μg/mL and a CC50 of 118.68 μg/mL.
    4,5-O-Dicaffeoyl quinic acid methyl ester
  • HY-109142
    Ziresovir
    		Inhibitor
    Ziresovir (AK0529;RO-0529) is a potent, selective, and orally bioavailable respiratory syncytial virus (RSV) fusion (F) protein (RSV F) protein inhibitor. Ziresovir shows anti-RSV activity (EC50=3 nM) and highlights pharmacokinetics in animal species.
    Ziresovir
  • HY-12983
    ALS-8112
    		Inhibitor 98.90%
    ALS-8112 is a potent and selective respiratory syncytial virus (RSV) polymerase inhibitor. The 5'-triphosphate form of ALS-8112 inhibits RSV polymerase with an IC50 of 0.02 μM.
    ALS-8112
  • HY-P9944
    Palivizumab
    		Inhibitor 99.43%
    Palivizumab (MEDI 493), a humanized respiratory syncytial virus monoclonal antibody, reduces respiratory syncytial virus (RSV) infection.
    Palivizumab
  • HY-102038
    PC786
    		Inhibitor 99.24%
    PC786 is an inhaled respiratory syncytial virus (RSV) L protein polymerase inhibitor. PC786 demonstrates potent antiviral activity against RSV-A (IC50 <0.09 to 0.71 nM) and RSV-B (IC50, 1.3 to 50.6 nM).
    PC786
  • HY-112180
    Rilematovir
    		Inhibitor 98.00%
    Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.
    Rilematovir
  • HY-146246
    EIDD-2749
    		Inhibitor 99.85%
    EIDD-2749 (4'-Fluorouridine) is an orally active RdRp inhibitor. EIDD-2749 effectively blocks the replication of RSV and SARS-CoV-2. EIDD-2749 also exhibits activity against HCV and lymphocytic choriomeningitis virus (LCMV). EIDD-2749 is a promising oral therapeutic candidate for COVID-19 and is also suitable for research on other RNA viruses.
    EIDD-2749
  • HY-16727
    Presatovir
    		Inhibitor 99.94%
    Presatovir (GS-5806) is an orally bioavailable RSV fusion inhibitor with a mean EC50 value of 0.43 nM.
    Presatovir
  • HY-123475
    Sisunatovir
    		Inhibitor 99.08%
    Sisunatovir (RV521), an orally available inhibitor of the RSV protein, exhibits potent efficacy against a panel of clinical isolates of RSV-A and RSV-B viruses, with IC50s of 1.4 nM and 1.0 nM, respectively.
    Sisunatovir
  • HY-12283
    Rostafuroxin
    		Inhibitor 98.00%
    Rostafuroxin (PST 2238), a digitoxigenin derivative, is an orally active and potent Na+,K+-ATPase (ATP1A1) antognist. Rostafuroxin binds specifically to the ATP1A1 extracellular domain and blocks respiratory syncytial virus (RSV)-triggered EGFR Tyr845 phosphorylation. Rostafuroxin has antihypertensive and anti-RSV activity.
    Rostafuroxin
  • HY-11097
    TMC353121
    		Inhibitor ≥98.0%
    TMC353121 is a potent respiratory syncytial virus (RSV) fusion inhibitor with pEC50 of 9.9.
    TMC353121
  • HY-P99209
    Motavizumab
    		98.35%
    Motavizumab (MEDI-524) is an anti-human RSV (respiratory syncytial virus) monoclonal antibody. Motavizumab can be used in respiratory syncytial virus infection in high-risk infants research.
    Motavizumab
  • HY-12983A
    Lumicitabine
    		Inhibitor 99.78%
    Lumicitabine (ALS-008176) is an inhibitor of the respiratory syncytial virus (RSV) polymerase.
    Lumicitabine
  • HY-145119AS
    Mindeudesivir hydrobromide
    		Inhibitor 99.46%
    Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19.
    Mindeudesivir hydrobromide
  • HY-P99756
    Nirsevimab
    		Inhibitor
    Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with modified Fc region, which can prolong its half-life. Nirsevimab has an affinity for RSV-B with an Kd value of 1.5 nM. Nirsevimab can be used for RSV research.
    Nirsevimab
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity